BZYR (Burzynski Research Institute) Total Liabilities: $0.07 Mil (As of Nov. 2025)


What is Burzynski Research Institute Total Liabilities?

Burzynski Research Institute BZYR -46.31% Total Liabilities is $0.07 Mil as of Nov. 2025.

Burzynski Research Institute's Total Liabilities for the quarter that ended in Nov. 2025 was $0.07 Mil.

Burzynski Research Institute's quarterly Total Liabilities stayed the same from May. 2025 ($0.07 Mil) to Aug. 2025 ($0.07 Mil) but then declined from Aug. 2025 ($0.07 Mil) to Nov. 2025 ($0.07 Mil).

Burzynski Research Institute's annual Total Liabilities increased from Feb. 2023 ($0.02 Mil) to Feb. 2024 ($0.03 Mil) and increased from Feb. 2024 ($0.03 Mil) to Feb. 2025 ($0.04 Mil).

Burzynski Research Institute Total Liabilities Historical Data

* Premium members only.

The historical data trend for Burzynski Research Institute's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Burzynski Research Institute Total Liabilities Chart

Burzynski Research Institute Annual Data
Trend Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.00 0.02 0.03 0.04

Burzynski Research Institute Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.04 0.07 0.07 0.07

Burzynski Research Institute Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Burzynski Research Institute's Total Liabilities for the fiscal year that ended in Feb. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.042+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.04

Total Liabilities=Total Assets (A: Feb. 2025 )-Total Equity (A: Feb. 2025 )
=0.001--0.042
=0.04

Burzynski Research Institute's Total Liabilities for the quarter that ended in Nov. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.07+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.07

Total Liabilities=Total Assets (Q: Nov. 2025 )-Total Equity (Q: Nov. 2025 )
=0.002--0.067
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $0.07 Mil mean?
Burzynski Research Institute (BZYR) has a Total Liabilities of $0.07 Mil as of Nov. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Burzynski Research Institute and its competitors.
Is Burzynski Research Institute's Total Liabilities too high?
Burzynski Research Institute's current Total Liabilities is $0.07 Mil.
How does Burzynski Research Institute's Total Liabilities compare to AGTX and EMMA?
Burzynski Research Institute's Total Liabilities of $0.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Burzynski Research Institute and its competitors. Burzynski Research Institute's current Total Liabilities is $0.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burzynski Research Institute stock overvalued right now?
Burzynski Research Institute (BZYR) has a current Total Liabilities of $0.07 Mil. The current Total Liabilities is $0.07 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Burzynski Research Institute (BZYR), the current Total Liabilities is $0.07 Mil as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Burzynski Research Institute Business Description

Address 9432 Katy Freeway, Houston, TX, USA, 77055
Burzynski Research Institute Inc operates as a research and development facility of Antineoplaston drugs currently being tested for the use in the treatment of cancer, and provides consulting services.